Market Updates
U.S. Movers: Birkenstock, General Mills, Jabil, Merck
Scott Peters
18 Dec, 2024
New York City
General Mills declined 5.7% to $62.0 despite the food product maker reporting better-than-expected sales in its quarter.
Merck & Co. increased 1.1% to $101.21, and the pharmaceutical company signed an exclusive global license agreement with the China-based Hansho Pharmaceuticals.
Merck plans to develop and commercialize a Chinese company's experimental obesity drug with an upfront payment of $112 million and additional milestone payments of up to $1.9 billion.
Birkenstock Holding PLC soared 5.6% to $58.89 after the designer sandals maker reported better-than-expected fiscal fourth quarter results, driven by higher full-price sales in the U.S. and Asia.
Revenue in the fiscal fourth quarter ending in September increased 21% to €1.8 billion from €1.49 billion, net income soared 155% to €191.6 million from €75 million, and diluted earnings per share advanced 161% to €1.02 from 41 cents a year ago.
The company registered a double-digit increase in sales across all regions, with sales in the Americas advancing 19%, in Europe gaining 21%, and Asia Pacific, the Middle East, and Africa soaring 42%.
Jabil Inc. surged 9.7% to $146.90 after the electronics manufacturing company reported better-than-expected fiscal first quarter earnings and the company lifted its full-year outlook.
Annual Returns
| Company | Ticker | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|
Earnings
| Company | Ticker | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|